ReviewDrugs2017
Psychiatric Symptoms in Patients with Cushing's Syndrome: Prevalence, Diagnosis and Management.
Review in Drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- Who and how to screen for Cushing's syndrome: the position statement of the Italian Society of Endocrinology.Journal of endocrinological investigation · 2026Guideline
- Pituitary adenomas and neuropsychological status: a systematic literature review.Neurosurgical review · 2020Pooled it
- Trial
- Trial
- Problem-solving therapy can reduce psychological distress in patients with Cushing's disease: a randomized controlled trial.Pituitary · 2022Trial
- Changes in Body Image and Pain in Patients with Cushing Syndrome: A Predictor for Depression and Vice Versa.Journal of the Endocrine Society · 2026Article
- Steroid alterations in Cushing's disease persist after remission: ACTH-driven steroid changes dissociate from mood-regulatory neurosteroids.Frontiers in endocrinology · 2026Article
- Traditional Chinese Medicine in Cushing's Syndrome: A Narrative Review of Pathophysiology and Potential Therapeutic Effects.OncoTargets and therapy · 2026Review
- From hypercortisolism to remission: impact of Cushing's disease on eating patterns.Frontiers in endocrinology · 2026Article
- A bibliometric analysis of Cushing's disease and magnetic resonance imaging: history, research hotspots, and emerging trends.Quantitative imaging in medicine and surgery · 2025Article
- Who and how to screen for endogenous hypercortisolism in patients with mood disorders.Journal of endocrinological investigation · 2025Review
- Research status and prospects of pituitary adenomas in conjunction with neurological and psychiatric disorders and the tumor microenvironment.Frontiers in neuroscience · 2024Review
- Reversibility of Impaired Large-Scale Functional Brain Networks in Cushing's Disease after Surgery Treatment: A Longitudinal Study.Neuroendocrinology · 2024Article
- Brain Tumor at Diagnosis: From Cognition and Behavior to Quality of Life.Diagnostics (Basel, Switzerland) · 2023Review
- Misdiagnosed psychiatric manifestations in a rare disease: a case report of secondary anxiety syndrome in Cushing's disease.Frontiers in psychiatry · 2023Article
- Cushing's Disease Presenting with Functional Neurological (Conversion) Disorder.Case reports in psychiatry · 2023Article
- Review
- Gene expression changes in the brain of a Cushing's syndrome mouse model.Journal of neuroendocrinology · 2022Article
- Pathophysiology of Mild Hypercortisolism: From the Bench to the Bedside.International journal of molecular sciences · 2022Review
- Psychotropic Drugs in Patients with Cushing's Disease Before Diagnosis and at Long-Term Follow-Up: A Nationwide Study.The Journal of clinical endocrinology and metabolism · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cushing's syndrome (CS) results from chronic exposure to cortisol excess, produced by the adrenal cortex. Hypercortisolism predisposes to psychiatric and neurocognitive disorders, mainly to depression and anxiety disorders. Screening tools to identify psychiatric symptoms are available for clinicians in their daily practice, although a specific diagnosis should be performed by specialists. Even if psychiatric symptoms improve after remission of hypercortisolism, complete recovery may not be achieved. Given the burden of these symptoms, psychiatric or psychological monitoring and treatment should be offered through all phases of CS, with a multidisciplinary approach. The aim of this article is to review data on the prevalence, diagnosis and management of psychiatric symptoms seen in patients with CS and to propose therapeutic approaches that may be followed in clinical practice. The prevalence of different psychiatric disorders has been described in both the active phase and after CS remission. Patients may not talk spontaneously about psychiatric symptoms they present, thus clinicians should ask directly about them. We recommend the use of screening tools in clinical practice to detect and treat these symptoms promptly. Even if reference endocrinologists cannot perform a definite psychiatric diagnosis, it will be important to ask patients directly about the presence of symptoms and refer if necessary to a psychiatrist. Additionally, patient information and educational programmes could be useful to manage psychiatric symptoms and to improve quality of life in patients with CS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.